Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study  

作　　者：Ruoyang Shao Yu Zhang Jinping He Fen Huang Zhiping Fan Kaibo Yang Yajing Xu Na Xu Yi Luo Lan Deng Xi Zhang Jia Chen Mingzhe Han Xudong Li Sijian Yu Hui Liu Xinquan Liang Xiaodan Luo Pengcheng Shi Zhixiang Wang Ling Jiang Xuan Zhou Ren Lin Yan Chen Sanfang Tu Jing Sun Yu Wang Qifa Liu Li Xuan 

机构地区：[1]Department of Hematology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China [2]clinical Medical Research Center of Hematology Diseases of Guangdong Province,Guangzhou 510515,China [3]Department of Hematology,Xiangya Hospital,Central South University,Changsha 410008,China [4]Bone Marrow Transplantation Center,the First Affliated Hospital,Zhejang University School of Medicine,Hangzhou 310oo9,China [5]Department of Hematology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China [6]Department of Hematology,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200125,China [7]Department of Hematology,Xinqiao Hospital,Third Military Medical University,Chongqing 400037,China [8]The First Affliated Hospital of Soochow University,Suzhou 215006,China [9]Hematopoietic Stem Cell Transplantation Center,Institute of Hematology and Blood Diseases Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Tianjin 300020,China [10]Department of Hematology,the Third Afliated Hospital of Sun Yat-Sen University,Guangzhou 510630,China [11]Department of Hematology,the First People's Hospitalf Chenzhou,Chenzhou 423099,China [12]Deparment of Hematlogy,the First Affiliated Hospitalof GuangzhouMedical University,Guangzhou 510120,China [13]Department of Hematology,the Fifth Affliated Hospital of Guangzhou Medical University,Guangzhou 510799,China [14]Department of Hematlogy,Peking University People's Hospital,Beijing 100044,China [15]Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics,NationalKey Discipline of Human Anatomy,School of Basic Medical Sciences,Southern Medical University,Guangzhou 510515,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第10期4903-4913,共11页信号转导与靶向治疗（英文）

基　　金：This work was supported by the National Natural Science Foundation of China(82170213 to L.X.,81970161 to Q.L.);the National Key Research and Development Projects of China(2021YFC2500301-4 to Q.L.,2022YFC2502600-5 to L.X.);Clinical Research Program of Nanfang Hospital,Southern Medical University(2021CR002 to L.X.).

摘　　要：Sorafenib therapy improves overall survival(OS)in patients with FLT3 internal tandem duplication(ITD)acute myeloid leukemia(AML)undergoing allogeneic hematopoietic stem cell transplantation.We explored the efficacy of sorafenib therapy in this population with different concomitant genetic patterns.In this multi-center,cohort study,we enrolled patients with FLT3-ITD AML undergoing allogenic hematopoietic cell transplantation.Patients with sorafenib maintenance post-transplantation for at least four weeks were allocated to the sorafenib group,and otherwise to the control group.

关 键 词：HEMATOPOIETIC SORAFENIB PATIENTS 

分 类 号：R733.7[医药卫生—肿瘤]